- Home
- ZVRA vs RIGL Comparison
ZVRA vs RIGL Comparison
Compare ZVRA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- RIGL
- Stock Information
- Founded
- ZVRA 2006
- RIGL 1996
- Country
- ZVRA United States
- RIGL United States
- Employees
- ZVRA N/A
- RIGL N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- RIGL Health Care
- Exchange
- ZVRA Nasdaq
- RIGL Nasdaq
- Market Cap
- ZVRA 419.5M
- RIGL 486.4M
- IPO Year
- ZVRA 2015
- RIGL 2000
- Fundamental
- Price
- ZVRA $7.69
- RIGL $20.09
- Analyst Decision
- ZVRA Strong Buy
- RIGL Buy
- Analyst Count
- ZVRA 7
- RIGL 5
- Target Price
- ZVRA $21.20
- RIGL $34.80
- AVG Volume (30 Days)
- ZVRA 374.9K
- RIGL 223.6K
- Earning Date
- ZVRA 03-27-2025
- RIGL 03-04-2025
- Dividend Yield
- ZVRA N/A
- RIGL N/A
- EPS Growth
- ZVRA N/A
- RIGL N/A
- EPS
- ZVRA N/A
- RIGL 0.22
- Revenue
- ZVRA $24,489,000.00
- RIGL $157,374,000.00
- Revenue This Year
- ZVRA N/A
- RIGL $51.34
- Revenue Next Year
- ZVRA $330.04
- RIGL $15.75
- P/E Ratio
- ZVRA N/A
- RIGL $91.32
- Revenue Growth
- ZVRA 47.85
- RIGL 21.65
- 52 Week Low
- ZVRA $4.20
- RIGL $7.48
- 52 Week High
- ZVRA $9.76
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- ZVRA 48.77
- RIGL 45.75
- Support Level
- ZVRA $7.64
- RIGL $20.00
- Resistance Level
- ZVRA $8.21
- RIGL $21.93
- Average True Range (ATR)
- ZVRA 0.29
- RIGL 1.30
- MACD
- ZVRA 0.03
- RIGL -0.27
- Stochastic Oscillator
- ZVRA 57.93
- RIGL 2.01
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.